ReviewTranslational cancer research2026
PARP inhibitors in the treatment of ovarian cancer: a narrative review.
Review in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Poly(ADP-ribose) polymerase inhibitors (PARPis) have fundamentally changed the treatment paradigm for patients with ovarian cancer, especially in tumors with homologous recombination deficiency (HRD). However, acquired resistance limits their long-term benefit. The purpose of the narrative review is to provide a comprehensive synthesis of the scientific and clinical evolution of PARPis, a critical analysis of the resistance mechanisms, and an evaluation of the emerging strategies for overcoming these challenges. Methods: We conducted a literature search of PubMed, MEDLINE, and Embase databases from January 2005 to November 2025. The search terms included "PARP inhibitor", "ovarian cancer", "synthetic lethality", "resistance", "homologous recombination deficiency", and the related medical subject headings (MeSH) terms. A small number of seminal historical studies published prior to 2005 were identified through existing knowledge and reference lists. Articles were selected based on their relevance to clinical development, mechanistic insights, and therapeutic strategies. As this is a narrative review, we prioritized data from large-scale randomized controlled trials, meta-analyses, and authoritative guidelines to ensure the highest level of evidence. Key Content and Findings: This review delineates the evolution of PARPis from the concept of synthetic lethality to their establishment as first-line maintenance therapy. It details the efficacy of major PARPis (olaparib, niraparib, rucaparib, and fuzuloparib) in pivotal trials. A major focus is placed on elucidating the diverse molecular pathways underlying resistance, including replication fork protection, drug efflux, and restoration of homologous recombination repair (HRR), and tumor microenvironment (TME) adaptations. The review also assesses next-generation strategies, such as combinations with antiangiogenics, immunotherapy, and novel DNA damage response (DDR) inhibitors, while critically appraising their current clinical status. Conclusions: PARPis have substantially reshaped the therapeutic landscape of ovarian cancer. Overcoming resistance requires a multipronged approach integrating deep molecular profiling, mechanism-informed combination therapies, and biomarker-driven clinical trial designs. Future progress hinges on translating biological insights into personalized treatment strategies to extend durable remission for a greater portion of patients, while also addressing the economic and ethical implications of long-term maintenance therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.